Krystal Biotech

112 articles with Krystal Biotech

• Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock

  11/29/2021

  Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $200 million underwritten public offering of its common stock.

• Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa

  11/29/2021

  Krystal Biotech, Inc. today announced positive topline results from the pivotal GEM-3 trial of investigational beremagene geperpavec (B-VEC), now known as VYJUVEKTM, for the treatment of dystrophic Epidermolysis Bullosa (dystrophic EB).

• Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress

  11/8/2021

  Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today reported financial results and key operational progress updates for the third quarter ending September 30, 2021.

• 

  Clinical Catch-Up: October 25-29

  11/1/2021

  Yet another busy week for clinical trial news. Here’s a look.

• Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa

  10/26/2021

  Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that the last participant has completed the 26-week dosing period and 30-day safety follow up visit in the GEM-3 study, Krystal’s pivotal Phase 3 clinical trial evaluating investigational beremagene geperpavec (B-VEC) as a topical gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB).

• Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis

  10/19/2021

  Krystal Biotech Inc. today announced the presentation of pre-clinical data describing the nonclinical pharmacology of nebulized KB407, a redosable gene therapy candidate for the treatment of cystic fibrosis, in a poster at the North American Cystic Fibrosis Conference (NACFC) taking place virtually November 2 – 5, 2021.

• Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT

  10/14/2021

  Krystal Biotech Inc., the leader in redosable gene therapies for rare diseases, announced that it will present pre-clinical pharmacology data on its second genetic pulmonary disease candidate KB408, for the treatment of alpha-1 antitrypsin deficiency, at the upcoming European Society of Gene & Cell Therapy Virtual Congress held October 19 – 22, 2021.

• Krystal Biotech and GeneDx Announce Collaboration to Provide No-charge Genetic Testing for Patients with Suspected Dystrophic Epidermolysis Bullosa (DEB)

  10/12/2021

  Krystal Biotech, Inc. today announced a collaboration offering no-charge genetic testing for all types of Epidermolysis Bullosa (EB).

• Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference

  10/1/2021

  Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced its participation in the Chardan Virtual 5th Annual Genetic Medicines Conference, taking place October 4-5, 2021.

• Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic Fibrosis

  9/29/2021

  Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, announced today that it has been granted approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to conduct a Phase 1 clinical study of inhaled KB407 in patients with cystic fibrosis (CF).

• Krystal Biotech Appoints Laurent Goux as General Manager of Europe

  9/15/2021

  Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the appointment of Laurent Goux as the General Manager of Europe.

• Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021

  9/9/2021

  Krystal Biotech Inc. today announced that it will present data on its lead product candidate beremagene geperpavec (B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB) at the upcoming DEBRA International Conference 2021.

• Krystal Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it will be featured as a presenting company at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference.

• Krystal Biotech Reports Second Quarter 2021 Financial Results and Provides Update on Operational Progress

  8/9/2021

  Krystal Biotech Inc., the leader in redosable gene therapies for rare diseases, reported financial results and key operational progress updates for the second quarter ending June 30, 2021.

• Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis

  7/1/2021

  Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced updated results from the Phase 1/2 clinical trial evaluating topical administration of KB105 in patients with autosomal recessive congenital ichthyosis (ARCI) associated with mutations in the TGM1 gene.

• Krystal Biotech to Participate in Upcoming Investor Conferences - June 03, 2021

  6/3/2021

  Krystal Biotech Inc., the leader in redosable gene therapies for rare diseases, announced participation in two upcoming virtual investor conferences.

• Krystal Biotech Reports First Quarter 2021 Financial Results and Provides Update on Operational Progress

  5/10/2021

  Completed enrollment in pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) Strong balance sheet with March 31, 2021 cash, cash equivalents and short-term investments of $403.4 million

• Krystal Biotech Appoints Andy Orth as Chief Commercial Officer

  5/3/2021

  Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, announced today the appointment of Andy Orth as Chief Commercial Office

• Krystal Biotech Announces Virtual Presentation of Data from its Vector-Encoded-Antibody Platform at ASGCT

  4/27/2021

  Krystal Biotech Inc., the leader in redosable gene therapies for rare diseases, announced that it will present preclinical data from its vector-encoded-antibody platform in a digital poster presentation at the upcoming American Society of Genetic & Cell Therapy Annual Meeting held virtually May 11-14, 2021.

• Krystal Biotech Provides Update on Pivotal GEM-3 Study of B-VEC for DEB

  4/26/2021

  Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced modifications to the Statistical Analysis Plan (SAP) in the ongoing Phase 3 study of B-VEC for the treatment of dystrophic epidermolysis bullosa (DEB) based on feedback from the U.S. Food and Drug Administration (FDA).